News coverage about Medifast (NYSE:MED) has trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Medifast earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the specialty retailer an impact score of 46.2532931770371 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several analysts have recently commented on MED shares. DA Davidson lifted their price target on shares of Medifast from $65.00 to $74.00 and gave the company a “buy” rating in a research report on Friday, September 15th. Sidoti reaffirmed a “neutral” rating and set a $55.00 price target (up previously from $49.00) on shares of Medifast in a research report on Thursday, September 21st. Finally, BidaskClub raised shares of Medifast from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th.

Medifast (NYSE:MED) traded down 0.63% during mid-day trading on Friday, hitting $59.60. 15,956 shares of the stock traded hands. Medifast has a 12 month low of $36.70 and a 12 month high of $61.31. The stock’s 50 day moving average is $56.68 and its 200-day moving average is $46.77. The company has a market cap of $711.03 million, a price-to-earnings ratio of 29.95 and a beta of 0.46.

Medifast (NYSE:MED) last announced its earnings results on Tuesday, August 8th. The specialty retailer reported $0.63 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.10. Medifast had a net margin of 8.62% and a return on equity of 24.25%. The firm had revenue of $75.70 million for the quarter, compared to analyst estimates of $71.96 million. During the same quarter last year, the business earned $0.63 earnings per share. Medifast’s revenue was up 6.5% compared to the same quarter last year. On average, equities research analysts anticipate that Medifast will post $2.12 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, November 9th. Investors of record on Friday, September 22nd will be given a dividend of $0.32 per share. The ex-dividend date is Thursday, September 21st. This represents a $1.28 dividend on an annualized basis and a yield of 2.13%. Medifast’s dividend payout ratio (DPR) is currently 64.32%.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/06/medifast-med-receives-media-impact-rating-of-0-19.html.

About Medifast

Medifast, Inc is engaged in the production, distribution and sale of weight loss, weight management and healthy living products, and other consumable health and nutritional products. Medifast product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products and vitamins.

Insider Buying and Selling by Quarter for Medifast (NYSE:MED)

Receive News & Stock Ratings for Medifast Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast Inc and related stocks with our FREE daily email newsletter.